Indoco Remedies Ltd. Q2 FY26 Results Analysis

Executive Summary Indoco Remedies demonstrated a robust top-line performance in Q2 FY26, coupled with a significant improvement in its bottom-line figures compared to the previous year. Detailed Financial Performance (Q2 FY26 vs. Q2 FY25) Revenue from Operations: The company achieved a strong 12% YoY growth in revenue, which increased to ₹485 crore from ₹433 crore in the corresponding quarter last fiscal. This signals healthy demand and positive business momentum. Net Loss: Profitability showed a marked improvement. The company successfully narrowed its consolidated net loss to ₹8 crore for the quarter. This is a significant recovery compared to the net loss of ₹9.6 crore reported in Q2 FY25. EBITDA & Margins: Operational performance was mixed. Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) grew by 6.6% YoY to ₹43.4 crore, up from ₹41 crore. However, the EBITDA margin saw a minor contraction of 40 basis points, settling at 9.0% compared to 9.4% in the year-ago period. Sequential Recovery (Q2 FY26 vs. Q1 FY26) The Q2 performance is particularly significant when viewed against the preceding quarter (Q1 FY26). The company has shown a substantial operational turnaround. In Q1 FY26 (June quarter), the company had reported a net loss of ₹35.6 crore and an EBITDA margin of just 4.06%. The Q2 results, therefore, reflect a strong sequential improvement in financial health, with losses reducing dramatically and margins more than doubling from the previous quarter. Market & Stock Context The market registered a positive response to the earnings improvement. Following the announcement, the shares of Indoco Remedies gained 1.5% to trade at ₹275. While the stock has appreciated by 14.4% over the last six months, it remains down approximately 18% on a year-to-date (YTD) basis, reflecting the operational challenges faced earlier in the financial year.